Sorrento TherapeuticsSRNE
13F holders, Q2 2024 (June 30)5holders −2
0new positions
1sold out
$0.01avg. 13F price*
At the end of Q2 2024, 5 institutions reported holding Sorrento Therapeutics Inc. (SRNE) in their 13F filings, down 2 from Q1 2024. 0 opened new positions and 1 sold out. The largest holders were Lattice Capital Management, LLC ($492), KLCM Advisors, Inc. ($285) and Huntington National Bank ($49).
- Company
- Sorrento Therapeutics Inc.
- CUSIP
- 83587F202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 22,250 shares sold, net −22,250 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Lattice Capital Management, LLC | 0.00% | No change | 51,800 | $492 |
| KLCM Advisors, Inc. | 0.00% | No change | 30,000 | $285 |
| Huntington National Bank | 0.00% | No change | 5,001 | $49 |
| AlphaMark Advisors, LLC | 0.00% | No change | 2,135 | $0 |
| SlateStone Wealth, LLC | 0.00% | No change | 21,433 | $0 |
"% of holder's portfolio" is SRNE's weight in each manager's 13F, not the share of Sorrento Therapeutics Inc. the manager owns.